Analysis on the management of type 2 inflammatory asthma from the guideline of Global Strategy for Asthma Management and Prevention.
10.3760/cma.j.cn112150-20230726-00033
- Author:
Wen Chao GUAN
1
;
Ruo Nan CHAI
1
;
Chong XU
1
;
Xin Zhuo WANG
1
;
He Hua HUANG
1
;
Yu Meng ZHAO
1
;
Hong Mei ZOU
1
Author Information
1. Department of Respiratory Medicine, General Hospital of the Northern Theater Command of the Chinese People's Liberation Army, Shenyang 110016, China.
- Publication Type:Journal Article
- MeSH:
Humans;
Asthma/prevention & control*
- From:
Chinese Journal of Preventive Medicine
2023;57(12):1964-1971
- CountryChina
- Language:Chinese
-
Abstract:
Bronchial asthma is a common chronic respiratory disease, which is involved in a variety of cells and cellular components. In 2019, the guidelines for the diagnosis and treatment of asthma issued by the Global Initiative for Asthma (GINA) Committee put forward the concept of type 2 inflammatory asthma for the first time. The updated evolution of GINA guidelines has promoted the development of biological agents and disease treatment, providing effective prevention and treatment for patients with severe asthma and improving disease outcome. This paper expounds the disease mechanism and management suggestions of type 2 inflammatory asthma in GINA guidelines, and analyzes the relevant clinical studies on targeted treatment of type 2 inflammatory asthma in recent years, in order to provide reference for in-depth understanding of level 3 prevention and management of patients with type 2 inflammatory asthma.
